Supernus Pharmaceuticals (SUPN) Payables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Payables data on file, last reported at $101.2 million in Q1 2026.

• Payables for Q1 2026 came in at $101.2 million, up 31.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.2 million (up 31.67% YoY), and the FY2025 annual result was $107.8 million, up 41.19% from the prior year.
• Payables eased to $101.2 million in Q1 2026 per SUPN's latest filing, from $107.8 million in the prior quarter.
• Over five years, Payables peaked at $498.3 million in Q4 2022 and troughed at $75.8 million in Q3 2024.
• A 5-year average of $139.0 million and a median of $86.4 million in 2024 frame the typical range for Payables.
• On a YoY basis, Payables climbed as much as 456.67% in 2023 and fell as far as 84.03% in 2023.
• A 5-year view of Payables shows it stood at $498.3 million in 2022, then tumbled by 84.03% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025, then declined by 6.08% to $101.2 million in 2026.
• Business Quant data shows SUPN's Payables at $101.2 million in Q1 2026, $107.8 million in Q4 2025, and $108.6 million in Q3 2025.